AUTHORS
Hugues de Lavallade, Dirk-Jan Eikema2, Joe Tuffnell3, Linda Koster4, Egor Kulagin, MD5, Victoria Potter, MBBS, BSc, FRACP, FRCPA6, Jane Felicity Apperley, FRCP, FRCPath, MB7, Peter Dreger, Prof. Dr. med.8, Omur Gokmen Sevindik, MD9, Peter Von Dem Borne, MD, PhD10, Claude-Éric Bulabois11, Tobias Gedde-Dahl12, Regis Peffault De Latour, MD, PhD13, Ioanna Sakellari14, Keith Wilson, MBBS, FRCP, FRCPath15, Pavel Jindra, PhD16, Chiara Nozzoli, MD17, Ludek Raida18, Aloysius Ho19, Harpreet Kaur, FRCPath, MRCP, MBChB20, Nicola Polverelli, MD21, Chris Armstrong, FRCPath, MRCP22, Guillermo Orti, MD23, Marie Robin, MD24, Yves Chalandon, MD25, Donal McLornan, MD, PhD26
AFFILIATIONS
1 Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
2 EBMT Leiden Study Unit, Leiden, Netherlands
3 EBMT Leiden Study Unit, Leiden, Netherlands
4 EBMT Leiden Study Unit, Leiden, Netherlands
5 RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation
6 Kings College Hospital London, London, United Kingdom
7 Imperial College Hammersmith London, London, United Kingdom
8 University of Heidelberg, Heidelberg, Germany
9 Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Istanbul, Turkey
10 Leiden University Hospital, Leiden, Netherlands
11 CHU Grenoble Alpes - Universite Grenoble Alpes, Grenoble, France
12 Oslo University Hospital, Rikshospitalet, Oslo, Norway
13 Hopital St. Louis, Paris, France
14 George Papanicolaou General Hospital, Thessaloniki, Greece
15 Cardiff University Hospital of Wales & Swansea, Cardiff, United Kingdom
16 Charles University Hospital, Pilzen, Czech Republic
17 Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
18 Olomouc University Hospital, Olomouc, Czech Republic
19 Singapore General Hospital, Singapore, Singapore
20 Sheffield Royal Hallamshire, Sheffield, United Kingdom
21 Unit of Bone Marrow Transplantation - Unit of Hematology, Fondazione IRCCS Policlinico San Matteo,, Pavia, Italy
22 Department of Haematology, St. James Hospital, Dublin, Ireland
23 Hospital Vall d`Hebron, Barcelona, Spain
24 Hopital St. Louis, Paris, France
25 Hôpitaux Universitaires De Genève, Faculty of Medicine, University of Geneva, Geneva, Switzerland
26 University College London Hospitals NHS Trust, London, United Kingdom
ABSTRACT
Introduction
A significant proportion of CML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) restart Tyrosine Kinase Inhibitor (TKI) following transplant to prevent relapse. There is however no data to support if TKI can be discontinued following allo-HCT and whether such patients can safely discontinue TKI remains controversial. Practices vary among transplant centres depending on countrywide practices, centre experience, duration of molecular remission and patients’ wish. Analysis of retrospective data on the outcome of patients who discontinue TKI after transplant may provide further insight. The present study objective is to investigate the outcome of patients with CML who discontinue TKI therapy after restarting TKI following allo-HCT.
Methods
Through the EBMT database of patients who received a first allo-HCT for CML between 2004 and 2021, we identified 159 CML patients who restarted TKI treatment post allo-HCT and stopped it after at least 3 months of TKI therapy.
Results
Out of 159 patients who discontinued TKI, 56 (39%) were in first chronic phase (CP1) at the time of allo-HCT, 70 (49%) in second or later chronic phase (CP2 and later) and 18 (13%) in accelerated or blastic phase (AP/BP) while disease stage at transplant was missing for 15 patients. Median age was 45 years (range 18.1-71.4) at the time of allo-HCT and 64% were male. Donor type was identical sibling in 70 (44%) patients, Matched Unrelated Donor (UD) in 55 (35%) and Mismatched UD in 21 (13%) patients respectively.
Regarding the number of TKI lines post allo-HCT, this was one in 124 (78%) patients, two in 29 (18%) and three or more in 6 (4%) patients. The last TKI given after allo-HCT was Imatinib in 28 (18%), Dasatinib in 70 (44%), Nilotinib in 32 (20%), Ponatinib in 24 (15%) and Bosutinib in 5 (3%) patients.
After a median time from TKI discontinuation of 54.5 months (95% CI, 40.1-67.2), Overall Survival (OS) was 80% (73-86%), 72% (65-80%) and 66% (58-75%) at 12, 36 and 60 months respectively after TKI discontinuation. The leading cause of death were graft-versus-host disease (GvHD) and relapse/progression accounting for 19 (41%) and 12 (23%) out of 46 patients with reported cause of deaths respectively.
OS for patients who were in CP1 (n=56) at the time of transplant was significantly better compared to those who were in CP2 or later (n=70), with 12, 36 and 60 months OS after TKI discontinuation of 89% vs 76%, 83% vs 69% and 77% v 63% respectively (p=0.043). However, the cumulative incidence of relapse/progression (with competing event Death) was not significantly different between both groups (60 months cumulative incidence post TKI discontinuation of 24% vs 17% for CP1 and CP2 or later respectively, p=0.2).
Patients who discontinued the last TKI fewer than 6 months after starting it had a worse OS post TKI discontinuation than those who had been on their latest post-transplant TKI for either 6-12 months or for more than 12 months, with 12, 36 and 60 months OS post TKI discontinuation of 69% vs 88% vs 54%, 59% vs 75% vs 91% and 55% vs 63% vs 82% respectively for each of the 3 time points (p=0.002).
Conclusion
Post-transplant TKI discontinuation appears safe in patients who receive an allo-HCT while still in first chronic phase (CP1), while patients in CP2 or later may have a worse outcome.Duration of the latest TKI treatment may impact success of post-transplant TKI discontinuation and these findings require further investigations in adjusted analysis.
DISCLOSURES
Hugues de Lavallade: No relevant conflicts of interest to declare.